NO990405L - Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler - Google Patents

Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler

Info

Publication number
NO990405L
NO990405L NO990405A NO990405A NO990405L NO 990405 L NO990405 L NO 990405L NO 990405 A NO990405 A NO 990405A NO 990405 A NO990405 A NO 990405A NO 990405 L NO990405 L NO 990405L
Authority
NO
Norway
Prior art keywords
indole
glycinamides
carbonyl
derivatives
substituted
Prior art date
Application number
NO990405A
Other languages
English (en)
Other versions
NO990405D0 (no
Inventor
Bernard Hulin
Judith Lee Treadway
William Holt Martin
Dennis Jay Hoover
Douglas Phillips
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO990405D0 publication Critical patent/NO990405D0/no
Publication of NO990405L publication Critical patent/NO990405L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Foreliggende oppfinnelse angår visse indol-2-karboks- amider som kan brukes som antidiabetiske midler.
NO990405A 1995-06-06 1999-01-28 Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler NO990405L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000442 WO1996039384A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Publications (2)

Publication Number Publication Date
NO990405D0 NO990405D0 (no) 1999-01-28
NO990405L true NO990405L (no) 1999-01-28

Family

ID=11004338

Family Applications (2)

Application Number Title Priority Date Filing Date
NO961664A NO306398B1 (no) 1995-06-06 1996-04-25 Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat
NO990405A NO990405L (no) 1995-06-06 1999-01-28 Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO961664A NO306398B1 (no) 1995-06-06 1996-04-25 Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat

Country Status (37)

Country Link
US (1) US6107329A (no)
EP (1) EP0832065B1 (no)
JP (1) JP3314938B2 (no)
KR (1) KR100191992B1 (no)
CN (2) CN1142492A (no)
AP (1) AP623A (no)
AR (1) AR003955A1 (no)
AT (1) ATE206702T1 (no)
AU (1) AU701465B2 (no)
BG (1) BG100547A (no)
BR (1) BR9602542A (no)
CA (2) CA2342471C (no)
CO (1) CO4700440A1 (no)
CZ (1) CZ157396A3 (no)
DE (1) DE69523182T2 (no)
DK (1) DK0832065T3 (no)
FI (1) FI974436A (no)
HR (1) HRP960244A2 (no)
HU (1) HUP9601475A2 (no)
IL (1) IL118029A0 (no)
IS (1) IS4341A (no)
LV (1) LV11613B (no)
MA (1) MA23866A1 (no)
MX (1) MX9709875A (no)
NO (2) NO306398B1 (no)
NZ (1) NZ286460A (no)
OA (1) OA10581A (no)
PL (1) PL314561A1 (no)
RU (1) RU2143424C1 (no)
SG (1) SG44947A1 (no)
SI (1) SI9600177A (no)
SK (1) SK69996A3 (no)
TN (1) TNSN96072A1 (no)
TR (1) TR199600456A2 (no)
TW (1) TW346485B (no)
WO (1) WO1996039384A1 (no)
YU (1) YU34896A (no)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
ATE344046T1 (de) 1997-04-15 2006-11-15 Csir Pflanzenextrakte mit appetitunterdrückender aktivität
UA57811C2 (uk) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) * 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
CZ20021492A3 (cs) 1999-11-04 2003-06-18 Ortho-Mcneil Pharmaceutical, Inc. Nepeptidové substituované benzothiazepiny jako antagonisté vazopresinu
BRPI0107715B8 (pt) 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
AU779266B2 (en) 2000-05-11 2005-01-13 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP2004529184A (ja) * 2001-05-10 2004-09-24 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 新規１−アミドメチルカルボニル−ピペリジン誘導体、該誘導体を製造するための方法及び中間体並びにこれらの化合物を含有している医薬
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
CA2464214C (en) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
JPWO2003037864A1 (ja) * 2001-10-29 2005-02-17 日本たばこ産業株式会社 インドール化合物及びその医薬用途
FR2834214B1 (fr) * 2001-12-28 2004-09-24 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
BR0307006A (pt) * 2002-01-18 2004-11-03 Pfizer Prod Inc Intermediários para preparar inibidores de glicogênio fosforilase
MXPA03000966A (es) * 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2004041780A2 (en) * 2002-11-07 2004-05-21 Pfizer Products Inc. N-(indole-2-carbonyl) amides as anti-diabetic agents
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
EP1594439A2 (en) * 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
US7595403B2 (en) 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
WO2004092158A1 (en) * 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
EP1633709A1 (en) * 2003-04-30 2006-03-15 Pfizer Products Inc. Anti-diabetic agents
WO2004103958A2 (en) * 2003-05-19 2004-12-02 Michigan State University Preparation of hymenialdisine derivatives and use thereof
BRPI0410445B1 (pt) * 2003-05-21 2017-11-28 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitor compound of glycogen phosphorylase, pharmaceutical composition comprising the same, process for its production and intermediate compounds
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
JP4579239B2 (ja) * 2003-06-17 2010-11-10 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防するためのジペプチジルペプチダーゼ阻害剤としてのシクロヘキシルグリシン誘導体
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR20070054762A (ko) 2003-11-12 2007-05-29 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
WO2006055435A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
US8691835B2 (en) 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
AU2006250354A1 (en) * 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CN102908351B (zh) 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
CN100519524C (zh) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
KR20090050081A (ko) * 2006-09-13 2009-05-19 사노피-아벤티스 응고 인자 ＩＸａ 억제제로서 사용하기 위한 이소세린 유도체
EP2096111A1 (en) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
CN101578264A (zh) * 2006-12-18 2009-11-11 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
CN101279955B (zh) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
JP6022769B2 (ja) 2008-04-28 2016-11-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール
WO2010007046A2 (en) * 2008-07-15 2010-01-21 Novartis Ag Organic compounds
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
RS53176B (en) 2010-02-03 2014-06-30 Takeda Pharmaceutical Company Limited KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
CN102453001B (zh) * 2010-10-22 2016-06-01 中国医学科学院药物研究所 硫代吗啉类化合物及其制备方法和用途
WO2012099785A2 (en) * 2011-01-20 2012-07-26 The Regents Of The University Of Colorado, A Body Corporate Modulators of tlr3/dsrna complex and uses thereof
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
EP2714660B1 (en) * 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
CN104053439B (zh) 2011-10-25 2016-08-24 詹森药业有限公司 1-(5,6-二氯-1h-苯并[d]咪唑-2-基)-1h-吡唑-4-羧酸的葡甲胺盐制剂
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
CN103497181B (zh) 2013-09-30 2016-03-30 承德医学院 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
SG11201607108XA (en) * 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108329330B (zh) * 2017-01-20 2021-05-04 复旦大学 2-苄氧苯基噁唑并吡啶类化合物及其药物用途
CN108191845A (zh) * 2018-02-12 2018-06-22 李化绪 一种异恶唑亚氨基类化合物及其在降血脂药物中的应用
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4836846A (en) * 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4764610A (en) * 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) * 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
US4933325A (en) * 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4757151A (en) * 1985-11-14 1988-07-12 Warner-Lambert Company 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
US4902708A (en) * 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) * 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
US5034376A (en) * 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
HU204285B (en) * 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
MY103189A (en) * 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
IL85728A (en) * 1987-03-25 1993-01-14 Bio Mega Inc Fluorine containing atrial natriuretic peptides, their preparation and pharmaceutical compositions containing them
EP0288965A2 (de) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en) * 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) * 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
EP0336356A3 (en) * 1988-04-05 1991-09-25 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
US4904846A (en) * 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
US5010089A (en) * 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr) * 1989-02-17 1993-11-05 Roussel Uclaf Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) * 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
DE69016760T2 (de) * 1989-12-04 1995-07-06 Searle & Co Heterozyklische Acylaminodiol-beta-aminosäure-Derivate.
EP0514442B1 (fr) * 1990-02-09 1994-04-27 Aventis Pharma S.A. N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant
EP0518961A1 (fr) * 1990-03-07 1992-12-23 Aventis Pharma S.A. Derives de glycinamide, leur preparation et les medicaments les contenant
JPH03294253A (ja) * 1990-04-12 1991-12-25 Shionogi & Co Ltd 消化管ホルモン拮抗物質
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (en) * 1992-09-18 1994-03-31 Japan Tobacco Inc. Alcohol derivative having renin-inhibiting activity and use thereof
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
EP0764151A2 (en) * 1994-06-10 1997-03-26 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates

Also Published As

Publication number Publication date
CA2224062C (en) 2001-09-04
AR003955A1 (es) 1998-09-30
LV11613B (en) 1997-04-20
NO961664L (no) 1996-12-09
AP623A (en) 1997-12-19
NO990405D0 (no) 1999-01-28
HU9601475D0 (en) 1996-07-29
PL314561A1 (en) 1996-12-09
SK69996A3 (en) 1997-08-06
NO961664D0 (no) 1996-04-25
DE69523182T2 (de) 2002-02-07
MA23866A1 (fr) 1996-12-31
CA2342471C (en) 2002-10-29
FI974436A0 (fi) 1997-12-05
AP9600803A0 (en) 1996-04-30
CN1098838C (zh) 2003-01-15
TR199600456A2 (tr) 1996-12-21
TNSN96072A1 (fr) 2005-03-15
AU701465B2 (en) 1999-01-28
MX9709875A (es) 1998-03-31
CN1140709A (zh) 1997-01-22
BG100547A (bg) 1996-12-31
WO1996039384A1 (en) 1996-12-12
JP3314938B2 (ja) 2002-08-19
RU2143424C1 (ru) 1999-12-27
CZ157396A3 (en) 1997-03-12
CO4700440A1 (es) 1998-12-29
NO306398B1 (no) 1999-11-01
CN1142492A (zh) 1997-02-12
ATE206702T1 (de) 2001-10-15
BR9602542A (pt) 1998-10-27
OA10581A (en) 2002-08-28
CA2342471A1 (en) 1996-12-12
IS4341A (is) 1996-12-07
CA2224062A1 (en) 1996-12-12
YU34896A (sh) 1999-09-27
US6107329A (en) 2000-08-22
DE69523182D1 (en) 2001-11-15
SI9600177A (en) 1997-02-28
KR970001322A (ko) 1997-01-24
KR100191992B1 (ko) 1999-06-15
EP0832065B1 (en) 2001-10-10
HRP960244A2 (en) 1997-12-31
AU5462696A (en) 1996-12-19
FI974436A (fi) 1998-01-27
IL118029A0 (en) 1996-08-04
DK0832065T3 (da) 2001-11-19
EP0832065A1 (en) 1998-04-01
HUP9601475A2 (hu) 1998-09-28
SG44947A1 (en) 1997-12-19
LV11613A (lv) 1996-12-20
TW346485B (en) 1998-12-01
JPH10511687A (ja) 1998-11-10
NZ286460A (en) 1998-09-24

Similar Documents

Publication Publication Date Title
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
NO962322D0 (no) Substituerte N-(indol-2-karbonyl)--alanimamider og derivater som antidiabetiske midler
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
FI925167A (fi) 2-substituerade sackarinderivat, som aer inhibitorer foer proteolytiska enzymer
NO944430D0 (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
DK0625987T3 (da) Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
DE69132423D1 (de) Inhibitoren retroviraler Proteasen
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
ATE203519T1 (de) Chinolinderivate als antimalariamittel
NO955288L (no) Skvalen-syntetase inhibitorer
FI955118A0 (fi) Herbisidiset substituoidut 1-fenyyli- tai 1-pyridinyyli-bentsotriatsolit
ATE320422T1 (de) Metalloproteinase inhibitoren
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
DK0950056T3 (da) N-(pyridinylamino)isoindoliner og beslægtede forbindelser
BG101145A (en) USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA
NO962015D0 (no) Pyron-derivater som protease-inhibitorer og antivirus-midler
ES2158441T3 (es) Arilheterociclos con actividad herbicida.
DK0703916T3 (da) 14-Substituerede marcfortiner og derivater, der kan anvendes som antispirant-midler
FI945414A (fi) Menetelmä N,N-disubstituoidun aminofenolin valmistamiseksi
ZA964409B (en) Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application